Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant growth factors.

L T Goodnough1, K C Anderson

  • 1Washington University School of Medicine, St Louis, MO 63110, USA.

Transfusion Science
|February 7, 1995
PubMed
Summary
This summary is machine-generated.

Recombinant growth factors like erythropoietin and myeloid growth factors significantly reduce blood transfusions and infections. Their use is guided by clinical indications and monitored by transfusion committees due to high costs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training.

mAbs·2025
Same author

Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.

Leukemia·2024
Same author

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Seminars in hematology·2023
Same author

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2019
Same author

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Leukemia·2018
Same author

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2017
Same journal

Discontinuous automated calcium supplementation during thrombocytapheresis with the haemonetics MCS+ version C.

Transfusion science·2002
Same journal

Is Brazil entering a new age?

Transfusion science·2001
Same journal

Is Brazil entering a new age?

Transfusion science·2001
Same journal

Post-transfusion thrombocytopenia in recipients with anti-HLA antibody.

Transfusion science·2000
Same journal

The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe(3+) values.

Transfusion science·2000
Same journal

A relationship between glucose metabolism and NO-mediated iron mobilization from cells.

Transfusion science·2000
See all related articles

Area of Science:

  • Hematology
  • Biotechnology
  • Clinical Medicine

Background:

  • Recombinant human growth factors are increasingly utilized in medical settings.
  • Growth factors have demonstrated efficacy in reducing reliance on allogeneic blood components and managing treatment side effects.
  • Examples include recombinant human erythropoietin for renal dialysis patients and myeloid growth factors post-chemotherapy.

Purpose of the Study:

  • To review emerging clinical guidelines for hematopoietic growth factor usage.
  • To highlight the impact of growth factors on blood component utilization.
  • To discuss the cost implications and monitoring of growth factor therapies.

Main Methods:

  • Review of emerging clinical guidelines.
  • Analysis of the impact of recombinant human growth factors on blood transfusion rates.

Related Experiment Videos

  • Examination of growth factor effects on infection rates and hospital stays.

    • Main Results:

    • Recombinant human erythropoietin has led to a substantial decline in blood transfusions for renal dialysis patients.
    • Myeloid growth factors have shown effectiveness in reducing infections and hospital stays by enhancing hematologic recovery after chemotherapy.
    • High costs necessitate targeted clinical application of these agents.

    Conclusions:

    • Hematopoietic growth factors offer significant clinical benefits but require judicious use based on established indications.
    • Hospital transfusion committees play a role in monitoring the appropriate application of these high-cost therapies.
    • Adherence to emerging clinical guidelines is crucial for optimizing patient outcomes and resource allocation.